🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

149 results for “recombinant” Clear

  1. Recombinant Factor VIIa BI (rFVIIa BI)

    Takeda

    Hemophilia A

    phase 3 mab completed

    1 trial

  2. Recombinant Human Albumin Injection

    The First People's Hospital of Lianyungang

    Hepatic Ascites

    phase 3 mab completed

    2 trials

  3. Recombinant Human Thrombopoietin (rhTPO)

    The First People's Hospital of Lianyungang

    Immune Thrombocytopenia

    phase 3 small molecule completed

    1 trial

  4. Recombinant Human VEGF Receptor-Fc Fusion Protein

    Biotech Pharmaceutical Co.,

    Neovascular Age-related Macular Degeneration

    phase 3 mab completed

    1 trial

  5. Recombinant Nonavalent (types 6/11/16/18/31/33/45/52/58) Human Papillomavirus (HPV) Vaccine (Escherichia coli)

    BRIGHT MINDS BIOSCIENCES INC.

    Human Papillomavirus Infection

    phase 3 mab active

    1 trial

  6. Recombinant Respiratory Syncytial Virus Vaccine (CHO Cell)

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Respiratory Syncytial Virus (RSV)

    phase 3 mab active

    1 trial

  7. Recombinant SARS-CoV-2 fusion protein vaccine (V-01)

    Livzon Pharmaceutical Group

    COVID-19 Pandemic

    phase 3 mab active

    1 trial

  8. Recombinant antihemophilic factor, plasma/albumin-free method (rAHF-PFM)

    Takeda

    Hemophilia A

    phase 3 mab terminated

    1 trial

  9. Recombinant factor IX

    Takeda

    Hemophilia B

    phase 3 mab completed

    1 trial

  10. Recombinant human hyaluronidase (rHuPH20)+ immune globulin intravenous (IGIV)

    Takeda

    Primary Immunodeficiency Diseases (PID)

    phase 3 mab completed

    1 trial

  11. Recombinant human luteinizing hormone (r-hLH)

    Merck KGaA, Darmstadt, Germany

    Hypogonadism

    phase 3 small molecule completed

    1 trial

  12. Recombinant human tissue kallikrein

    DiaMedica Therapeutics

    Acute Stroke

    phase 3 small molecule active

    1 trial

  13. Recombinant von Willebrand factor (rVWF)

    Takeda

    Von Willebrand Disease

    phase 3 mab completed

    2 trials

  14. SODIUM CHLORIDE, Gardasil 9 suspension for injection in a pre-filled syringe. Human Papillomavirus 9-valent Vaccine (Recombinant, adsorbed)

    Pari Pharma GmbH

    HPV vaccine

    phase 3 small molecule active

    1 trial

  15. Shingrix powder and suspension for suspension for injection Herpes zoster vaccine (recombinant, adjuvanted), Cladribine Placebo, cladribine

    Merck Sharp and Dohme

    Generalized Myasthenia Gravis

    phase 3 small molecule active

    1 trial

  16. recombinant human erythropoietin

    The First People's Hospital of Lianyungang

    Lymphoma

    phase 3 small molecule active

    1 trial

  17. recombinant human thrombopoietin

    The First People's Hospital of Lianyungang

    Immune Thrombocytopenia

    phase 3 small molecule active

    1 trial

  18. recombinant human thrombopoietin (rhTPO); dexamethasone

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Purpura

    phase 3 small molecule completed

    1 trial

  19. recombinant human thrombopoietin (rhTPO); rituximab

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Purpura

    phase 3 small molecule terminated

    1 trial

  20. recombinant interferon alfa

    United Therapeutics Europe Ltd

    Melanoma (Skin)

    phase 3 mab completed

    1 trial

  21. rhIDU (recombinant human-Alpha-L-Iduronidase)

    BioMarin Pharmaceutical Australia Pty Ltd

    Mucopolysaccharidosis I

    phase 3 mab completed

    1 trial

  22. rituximab; recombinant human thrombopoietin (rhTPO)

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Purpura

    phase 3 small molecule completed

    1 trial

  23. von Willebrand factor (Recombinant)

    Takeda

    Von Willebrand Disease

    phase 3 mab completed

    1 trial

  24. Aerosolized, Recombinant Alpha 1-Antitrypsin

    Takeda

    Alpha1-antitrypsin Deficiency

    phase 2 small molecule completed

    2 trials

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources